FDA Expands Approval of J&J Prostate Cancer Drug

By: Associated Press
By: Associated Press

The Food and Drug Administration has expanded approval of Johnson & Johnson's prostate cancer pill Zytiga for men with an earlier stage of the disease.

The agency says Zytiga is now approved for late-stage prostate cancer patients who have not yet received chemotherapy, based on study results showing it can extend life by up to five months when taken by men in that group.

The FDA previously approved the drug in April 2011 who for men with prostate cancer who have already taken the chemotherapy drug docetaxel.

Zytiga works by decreasing the male hormone testosterone.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
KOLN-TV Call: (402) 467-4321 Toll-free: 1-800-475-1011 840 North 40th Lincoln, NE 68503 Email: info@1011now.com KGIN-TV Call: (308) 382-6100 123 N Locust Street Grand Island, NE 68802 Email: kgin@1011now.com KSNB-TV Toll free 888-475-1011 123 N. Locust St. Grand Island, NE 68802 Email : ksnb@1011now.com
Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 183345151 - 1011now.com/a?a=183345151
Gray Television, Inc.